ES2059115T3 - Formulacion de eritropoyetina mejorada a base de ciclodextrina. - Google Patents

Formulacion de eritropoyetina mejorada a base de ciclodextrina.

Info

Publication number
ES2059115T3
ES2059115T3 ES91902955T ES91902955T ES2059115T3 ES 2059115 T3 ES2059115 T3 ES 2059115T3 ES 91902955 T ES91902955 T ES 91902955T ES 91902955 T ES91902955 T ES 91902955T ES 2059115 T3 ES2059115 T3 ES 2059115T3
Authority
ES
Spain
Prior art keywords
erythropoyetine
formulation
cyclodextrin based
based improved
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91902955T
Other languages
English (en)
Inventor
Frank J Konings
Marcus J M Noppe
Jean L Mesens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10670074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2059115(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2059115T3 publication Critical patent/ES2059115T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Re-Forming, After-Treatment, Cutting And Transporting Of Glass Products (AREA)
  • Processing Of Stones Or Stones Resemblance Materials (AREA)
  • Manufacturing Of Magnetic Record Carriers (AREA)
  • Perforating, Stamping-Out Or Severing By Means Other Than Cutting (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ESTE INVENTO MUESTRA UNA NUEVA COMPOSICION FARMACEUTICA PARA LA ADMINISTRACION LOCAL Y PARENTERAL QUE COMPRENDE UNA SOLUCION ACUOSA DE ERITROPOYETINA Y UN DERIVADO HIDROXILAQUILO (BETA)-/ O YCICLODEXTRINA. EL INVENTO MUESTRA TAMBIEN NUEVAS COMPOSICIONES DE ERITROPOYETINA LIOFILIZADA O SECADA MEDIANTE SPRAY QUE COMPRENDEN UN DERIVADO HIDROXILAQUILO (BETA)-/ O Y-CICLODEXTRINA, PROCESOS PARA PREPARAR TALES COMPOSICIONES ACUOSAS, LIOFILIZADAS O SECADAS POR SPRAY Y UN METODO PARA ESTABILIZAR SIMULTANEAMENTE ERITROPOYETINA EN UNA SOLUCION ACUOSA E IMPEDIR QUE SEA ADSORBIDA A SUPERFICIES.
ES91902955T 1990-01-29 1991-01-25 Formulacion de eritropoyetina mejorada a base de ciclodextrina. Expired - Lifetime ES2059115T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909001987A GB9001987D0 (en) 1990-01-29 1990-01-29 Improved cyclodextrin based erythropietin formulation

Publications (1)

Publication Number Publication Date
ES2059115T3 true ES2059115T3 (es) 1994-11-01

Family

ID=10670074

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91902955T Expired - Lifetime ES2059115T3 (es) 1990-01-29 1991-01-25 Formulacion de eritropoyetina mejorada a base de ciclodextrina.

Country Status (20)

Country Link
US (1) US5376632A (es)
EP (1) EP0513072B1 (es)
JP (1) JP2997052B2 (es)
KR (1) KR0183445B1 (es)
AT (1) ATE107518T1 (es)
AU (1) AU648061B2 (es)
CA (1) CA2074820C (es)
DE (1) DE69102627T2 (es)
DK (1) DK0513072T3 (es)
ES (1) ES2059115T3 (es)
FI (1) FI105012B (es)
GB (1) GB9001987D0 (es)
HU (1) HU218213B (es)
IE (1) IE65209B1 (es)
IL (1) IL97019A (es)
NO (1) NO304728B1 (es)
NZ (1) NZ236938A (es)
PT (1) PT96593B (es)
WO (1) WO1991011200A1 (es)
ZA (1) ZA91620B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
IL116085A (en) 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
US5754937A (en) 1996-05-15 1998-05-19 Stackpole Limited Hi-density forming process
PT977582E (pt) * 1997-03-18 2002-12-31 Roche Diagnostics Gmbh Preparacoes farmaceuticas associadas contendo eritropoietina e preparacoes de ferro
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
AU757896B2 (en) * 1998-09-02 2003-03-13 Allergan, Inc. Preserved cyclodextrin-containing compositions
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
PT1181036E (pt) * 1999-04-09 2008-10-03 Ortho Mcneil Pharm Inc Composições farmacêuticas de eritropoietina
WO2002011753A1 (en) * 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
US20060235366A1 (en) * 2000-12-20 2006-10-19 Fox Hollow Technologies, Inc. Method of evaluating a treatment for vascular disease
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
EP1413310A1 (en) * 2001-07-09 2004-04-28 Yamanouchi Pharmaceutical Co. Ltd. Sustained-release compositions for injection and process for producing the same
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
BRPI0411114B8 (pt) 2003-06-10 2021-05-25 Lg Chemical Ltd solução aquosa estável de eritropoetina humana, não contendo albumina de soro
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20110236902A1 (en) * 2004-12-13 2011-09-29 Tyco Healthcare Group Lp Testing a patient population having a cardiovascular condition for drug efficacy
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
MY150649A (en) 2006-10-20 2014-02-14 Icos Corp Compositions of chk1 inhibitors
EP2590666B1 (en) * 2010-07-06 2017-04-26 Augustinus Bader Topical application of erythropoietin for use in the treatment of injuries of the cornea
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
US11583584B1 (en) * 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4920214A (en) * 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
EP0308181A1 (en) * 1987-09-14 1989-03-22 Novo Nordisk A/S Trans-mucosal delivery formulations and a method for preparation thereof
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers

Also Published As

Publication number Publication date
NZ236938A (en) 1992-07-28
HU9202432D0 (en) 1992-10-28
IL97019A (en) 1997-07-13
ATE107518T1 (de) 1994-07-15
HUT62198A (en) 1993-04-28
NO922990L (no) 1992-07-29
ZA91620B (en) 1992-10-28
IE910286A1 (en) 1991-07-31
DK0513072T3 (da) 1994-08-01
JPH05503700A (ja) 1993-06-17
CA2074820A1 (en) 1991-07-30
NO922990D0 (no) 1992-07-29
CA2074820C (en) 2003-10-14
JP2997052B2 (ja) 2000-01-11
HU218213B (hu) 2000-06-28
DE69102627T2 (de) 1994-11-03
FI923402A0 (fi) 1992-07-28
FI105012B (fi) 2000-05-31
KR0183445B1 (en) 1999-05-01
EP0513072A1 (en) 1992-11-19
IL97019A0 (en) 1992-03-29
DE69102627D1 (de) 1994-07-28
EP0513072B1 (en) 1994-06-22
US5376632A (en) 1994-12-27
AU648061B2 (en) 1994-04-14
AU7149791A (en) 1991-08-21
NO304728B1 (no) 1999-02-08
GB9001987D0 (en) 1990-03-28
PT96593A (pt) 1991-10-15
WO1991011200A1 (en) 1991-08-08
FI923402L (fi) 1992-07-28
PT96593B (pt) 2001-06-29
IE65209B1 (en) 1995-10-04

Similar Documents

Publication Publication Date Title
ES2059115T3 (es) Formulacion de eritropoyetina mejorada a base de ciclodextrina.
NO180538C (no) N-sulfonyl-2-oksoindol-derivater som har affinitet for vasopressin- og/eller ocytocin-reseptorer, farmasöytiske blandinger som inneholder dem og mellomprodukter ved fremstilling av derivatene
NL980012I2 (nl) Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.
DK0639577T3 (da) Phosphonooxymethyl- eller methylthiomethylestere af taxanderivater som antitumormidler
AR024634A1 (es) Composicion farmaceutica estabilizada en forma liofilizada
ES2012809B3 (es) Derivados del taxol, su preparacion y composiciones farmaceuticas que los contienen.
SE9301539L (sv) Icke-migrerande 1-hydrokarbyloxi-2,2,6,6-tetrametylpiperidin- 1,3,5-triazinderivat som polymerstabilisator
ITMI921601A1 (it) Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
AR021462A1 (es) Composiciones acuosas alcalinas de limpieza y tratamiento de superficies duras.
DK0513675T3 (da) Hidtil ukendt peptidforbindelse samt fremgangsmåde til fremstilling deraf
NO961693D0 (no) Delta16-umettede C17-heterocykliske steroider som er anvendbare som steroid C17-20-lyaseinhibitorer
ES2066510T3 (es) Nuevos polipeptidos con afinidad para lipopolisacaridos y sus usos.
MX9307610A (es) Decapeptido modificado en la posicion 6 y composicion farmaceutica que locontiene.
DK0577745T3 (da) Bis-naphtalimider indeholdende amid- og thioamid-forbindelsesstykker som anticancermidler.
ES2061564T3 (es) Nuevo procedimiento para la preparacion de derivados de 6,7-diacil-7-desacetilforscolina.
FI822671L (fi) Aminoglykosidderivat, foerfaranden foer framstaellning av dem, farmaceutiska kompositioner innehaollande dem samt anvaendning av saodana derivat som laekemedel
ES2056617T3 (es) Formulacion de liposomas, aplicable de forma parenteral, constituida por lipidos sinteticos.
DK0443957T3 (da) Hidtil ukendte steroid-forbindelser med en spirogruppe i position 17, en fremgangsmåde og mellemprodukter til fremstilling deraf, deres anvendelse som lægemiddel og farmaceutiske præparater med indhold deraf
ES2118846T3 (es) Formas cristalinas de monohidrato de hidrocloruro de endo-2,3-dihidro-n-(8-metil-8-azabiciclo(3.2.1)oct-3-il)-2-oxo-1h-bencimidazol-1-carboxamida y de monohidrato de hidrocloruro de endo-3-etil-2,3-dihidro-n-(8-metil-8-azabiciclo(3.2.1)oct-3-il)-2-oxo-1h-bencimidazol-1-carboxamid
ES2053880T3 (es) Utilizacion de derivados de adenosina en la preparacion de composiciones farmaceuticas que poseen actividad inmunoestimulante.
ES2063014T3 (es) Derivados de 2-oxa-isocefemo, composiciones que los contienen y procedimientos de preparacion.
AR004029A1 (es) Nuevas formulaciones farmaceuticas
ITUD950183A3 (it) Sistema di connessione per parti di mobili
IT1264495B1 (it) Complessi solubili in acqua di glicosaminoglicani, loro procedimento di preparazione e composizioni farmaceutiche che li contengono
ECSP982538A (es) Formulaciones farmaceuticas que contienen variconazol

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 513072

Country of ref document: ES